Clinical Trial Update: An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants [Phase 4]

View source ↗

Summary

A Phase 4 efficacy and safety study of oxybutynin chloride OROS in Korean adults with overactive bladder completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Oxybutynin chloride OROS (oxybutynin chloride)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Urinary Bladder, Overactive | Phase 4 | Status: COMPLETED | Results posted: 2013-09-16